Project Oncology®
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.
Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.
Episodes 76-90 of 326
Personalized Treatment Pathways in Endometrial Cancer: A Molecular Approach
Project Oncology®Personalized Treatment Pathways in Endometrial Cancer: A Molecular Approach
Navigating Fertility Preservation in Young Patients With Endometrial Cancer
Project Oncology®Navigating Fertility Preservation in Young Patients With Endometrial Cancer
Subcutaneous Isatuximab Matches IV in Multiple Myeloma: Insights from IRAKLIA
Project Oncology®Subcutaneous Isatuximab Matches IV in Multiple Myeloma: Insights from IRAKLIA
Redefining Cancer Care with Functional Precision Medicine
Project Oncology®Redefining Cancer Care with Functional Precision Medicine
Patient Perspectives on Subcutaneous vs IV Immunotherapies in Oncology Care
Project Oncology®Patient Perspectives on Subcutaneous vs IV Immunotherapies in Oncology Care
From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
Project Oncology®From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
- advertisement
Optimizing Immunotherapy for Advanced NSCLC: How to Manage Immune Toxicities
Project Oncology®Optimizing Immunotherapy for Advanced NSCLC: How to Manage Immune Toxicities
Optimizing Second-Line CAR T Decisions in R/R Large B-Cell Lymphoma
Project Oncology®Optimizing Second-Line CAR T Decisions in R/R Large B-Cell Lymphoma
Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
Project Oncology®Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
Optimizing PI3Kα Testing and Therapy in HR+/HER2- Advanced Breast Cancer Care
Project Oncology®Optimizing PI3Kα Testing and Therapy in HR+/HER2- Advanced Breast Cancer Care
Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors
Project Oncology®Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors
Targeting PI3Kα-Mutated HR+/HER2- Breast Cancer in the Second-Line Setting
Project Oncology®Targeting PI3Kα-Mutated HR+/HER2- Breast Cancer in the Second-Line Setting
- advertisement
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Project Oncology®Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Project Oncology®Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
Project Oncology®Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
